Culverwell Anthony James bought QNRX
August 31, 2026 · Form 4 insider transaction
Culverwell Anthony James bought 3,073 shares of Quoin Pharmaceuticals, Ltd., a transaction worth N/A. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 1 day after the transaction.
Footnotes
Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.; The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.; The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.; Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.